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Tumors are complex organs composed of reciprocally interacting
cell types including cancer-initiating cells, more or less differen-
tiated cancer cells, extracellular matrix (ECM), and a variety of
stromal cells such as endothelial cells, immune cells, pericytes,
adipocytes, and fibroblasts (1). The tumor microenvironment
(TME) comprises a variety of cell types lying among a network
of various ECM fibers merged within the interstitial fluid and
gradients of several chemical compounds, which constantly inter-
play with malignant cells (2). The TME is also energetically linked
to cancer cells, which orchestrates functional changes in mito-
chondria of tumor cells that accompanies resistance to intrinsic
apoptotic stimuli and contributes to hypoxia (3). The interaction
of tumor resident cells impacts on the composition and texture
of the matrix, including its stiffness. Tumor cells interacting with
fibroblastic microenviroment might undergo a peculiar pheno-
typic change, known as epithelial–mesenchymal transition (2, 4,
5), and gain a pseudomesenchymal phenotype. These transdif-
ferentiated cancer cells promote stiffening of their environment,
which in turn feeds back in form of loss of tissue architecture or
induction of cell invasion (2). Additionally, the ECM components
shape the immune properties of dendritic cells (DCs) in the tumor
(6), and finally contribute to an anergic state in these cells, favor-
ing tumor immune-escape. Benencia et al. in this Research Topic
discuss that this “immune paralysis” of cancer-associated DCs can
be overcome in an experimental setting by blocking interleukin
(IL)-10R while simultaneously activating specific pattern recogni-
tion receptors (6). In agreement, also Accolla et al. describes that
the establishment of a pro-tumor environment is not the cause but
simply the consequence of the tumor strategy to primarily coun-
teract components of the adaptive cellular immunity, particularly
T helper lymphocytes (7).
Stroma cells within the TME might show diverse polarization
states, which is well-known in case of immune cells (8), but is
a novel assumption in case of carcinoma-associated fibroblasts
(CAFs) (1). Within the TME immune cells might destroy can-
cer cells, or they may promote tumor growth and dissemination,
which is largely due to different polarization of them (8). Also, the
CAFs have more populations, including the one, which is assigned
with pro-tumorigenic effects as stimulating tumor growth and
progression, and also the one, which might have tumor-inhibitory
effects (1). The novel point of view is the acknowledgment of
the plasticity and polarized phenotype both in the tumor cell
populations and also in the microenvironment (1, 8). The polar-
ized phenotypes and plasticity in both tumor cells and stroma
enables a dynamic array of inhibitory and stimulatory signals in
the tumor organ, which represents a new challenge for inves-
tigation of interactive processes instead of assuming cells with
predefined roles. This is the basis of a continuous evolution of the
tumor tissue.
According to contributions to this research topic (6, 7) the
dynamism of TME might be influenced. The optimal initiation
of the adaptive immune response dictated by adequate antigen
availability, as evidenced by several research groups and reviewed
by Accolla et al. is sufficient to reorient the TME from a pro-tumor
to an anti-tumor one (7).
Similarly to immune cells, also fibroblasts might contribute to
pro and to anti-TME. In an original article of Kaler et al. (9),
authors report that normal intestinal fibroblasts activate STAT1
signaling in colon cancer cells and, in contrast to CAFs, inhibit
growth of tumor cells (9). Interestingly, the proinflammatory
cytokine TNFα could release this inhibition.
Detailed analysis of not only the potent mediators but also
the signaling components is required in the stromal component
of the tumor tissue in addition to tumor cells. Investigation of
the signaling in stroma independently from tumor cells is a novel
challenge, which is elegantly addressed by Wallace et al. They uti-
lized two model systems: one where protein kinase C β (PKCβ)
was deleted in both the epithelial and stromal compartments,
and second, where PKCβ was deleted only in the stromal com-
partment (10). Mice globally lacking PKCβ were living longer
and developed smaller tumors, and when PKCβ was exclusively
lacking in the stroma, breast cancer tumor cells formed smaller
tumors as well, with diminished collagen deposition. Interestingly,
the stroma PKCβ-loss had no effect on tumor cell proliferation,
vascularization, or macrophage infiltration (10). In summary, this
research topic highlights the importance of the investigation and
targeting of TME dynamism, and of understanding the stroma cell
polarization.
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